Moderna joins the Association of the British Pharmaceutical Industry 

Moderna has become the newest member of the UK’s pharmaceutical industry body, the Association of the British Pharmaceutical Industry (ABPI), building on the long-term commitment by the American-based company to expand its footprint and investment in the UK. 

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reportedly has ‘high ambitions’ for rapid global growth. Key to these ambitions will be a new vaccine research, development and manufacturing facility in the UK, creating new jobs and building up the UK’s life sciences ecosystem. 

Darius Hughes, UK General Manager, Moderna, said: “This alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.” 

Richard Torbett, Chief Executive, ABPI, said: “With Moderna’s help we will be in an even stronger position to make the UK the best place in the world to research, develop and use new medicines and vaccines.” 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free